Cargando…

Serum N-terminal pro-B-type natriuretic peptide and cystatin C for acute kidney injury detection in critically ill adults in China: a prospective, observational study

OBJECTIVE: Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cystatin C (sCysC) are available clinically and beneficial in diagnosing acute kidney injury (AKI). Our purpose is to identify the performance of their combined diagnosis for AKI in critically ill patients. DESIGN: A prospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Jia, He, Linling, Liang, Yufan, Hu, Linhui, Xu, Jing, Fang, Heng, Li, Ying, Chen, Chunbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887693/
https://www.ncbi.nlm.nih.gov/pubmed/36717146
http://dx.doi.org/10.1136/bmjopen-2022-063896
_version_ 1784880389215485952
author Deng, Jia
He, Linling
Liang, Yufan
Hu, Linhui
Xu, Jing
Fang, Heng
Li, Ying
Chen, Chunbo
author_facet Deng, Jia
He, Linling
Liang, Yufan
Hu, Linhui
Xu, Jing
Fang, Heng
Li, Ying
Chen, Chunbo
author_sort Deng, Jia
collection PubMed
description OBJECTIVE: Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cystatin C (sCysC) are available clinically and beneficial in diagnosing acute kidney injury (AKI). Our purpose is to identify the performance of their combined diagnosis for AKI in critically ill patients. DESIGN: A prospectively recruited, observational study was performed. SETTING: Adults admitted to the intensive care unit of a tertiary hospital in China. PARTICIPANTS: A total of 1222 critically ill patients were enrolled in the study. MAIN OUTCOME MEASURES: To identify the performance of the combined diagnosis of serum NT-proBNP and sCysC for AKI in critically ill patients. The area under the receiver operating characteristic curve (AUC-ROC), category-free net reclassification index (NRI) and incremental discrimination improvement (IDI) were utilised for comparing the discriminative powers of a combined and single biomarker adjusted model of clinical variables enriched with NT-proBNP and sCysC for AKI. RESULTS: AKI was detected in 256 out of 1222 included patients (20.9%). AUC-ROC for NT-proBNP and sCysC to detect AKI had a significantly higher accuracy than any individual biomarker (p<0.05). After multivariate adjustment, a level of serum NT-proBNP ≥204 pg/mL was associated with 3.5-fold higher odds for AKI compared with those below the cut-off value. Similar results were obtained for sCysC levels (p<0.001). To detect AKI, adding NT-proBNP and sCysC to a clinical model further increased the AUC-ROC to 0.859 beyond that of the clinical model with or without sCysC (p<0.05). Moreover, the addition of these two to the clinical model significantly improved risk reclassification of AKI beyond that of the clinical model alone or with single biomarker (p<0.05), as measured by NRI and IDI. CONCLUSIONS: In critically ill individuals, serum NT-proBNP, sCysC and clinical risk factors combination improve the discriminative power for diagnosing AKI.
format Online
Article
Text
id pubmed-9887693
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-98876932023-02-01 Serum N-terminal pro-B-type natriuretic peptide and cystatin C for acute kidney injury detection in critically ill adults in China: a prospective, observational study Deng, Jia He, Linling Liang, Yufan Hu, Linhui Xu, Jing Fang, Heng Li, Ying Chen, Chunbo BMJ Open Intensive Care OBJECTIVE: Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cystatin C (sCysC) are available clinically and beneficial in diagnosing acute kidney injury (AKI). Our purpose is to identify the performance of their combined diagnosis for AKI in critically ill patients. DESIGN: A prospectively recruited, observational study was performed. SETTING: Adults admitted to the intensive care unit of a tertiary hospital in China. PARTICIPANTS: A total of 1222 critically ill patients were enrolled in the study. MAIN OUTCOME MEASURES: To identify the performance of the combined diagnosis of serum NT-proBNP and sCysC for AKI in critically ill patients. The area under the receiver operating characteristic curve (AUC-ROC), category-free net reclassification index (NRI) and incremental discrimination improvement (IDI) were utilised for comparing the discriminative powers of a combined and single biomarker adjusted model of clinical variables enriched with NT-proBNP and sCysC for AKI. RESULTS: AKI was detected in 256 out of 1222 included patients (20.9%). AUC-ROC for NT-proBNP and sCysC to detect AKI had a significantly higher accuracy than any individual biomarker (p<0.05). After multivariate adjustment, a level of serum NT-proBNP ≥204 pg/mL was associated with 3.5-fold higher odds for AKI compared with those below the cut-off value. Similar results were obtained for sCysC levels (p<0.001). To detect AKI, adding NT-proBNP and sCysC to a clinical model further increased the AUC-ROC to 0.859 beyond that of the clinical model with or without sCysC (p<0.05). Moreover, the addition of these two to the clinical model significantly improved risk reclassification of AKI beyond that of the clinical model alone or with single biomarker (p<0.05), as measured by NRI and IDI. CONCLUSIONS: In critically ill individuals, serum NT-proBNP, sCysC and clinical risk factors combination improve the discriminative power for diagnosing AKI. BMJ Publishing Group 2023-01-30 /pmc/articles/PMC9887693/ /pubmed/36717146 http://dx.doi.org/10.1136/bmjopen-2022-063896 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Intensive Care
Deng, Jia
He, Linling
Liang, Yufan
Hu, Linhui
Xu, Jing
Fang, Heng
Li, Ying
Chen, Chunbo
Serum N-terminal pro-B-type natriuretic peptide and cystatin C for acute kidney injury detection in critically ill adults in China: a prospective, observational study
title Serum N-terminal pro-B-type natriuretic peptide and cystatin C for acute kidney injury detection in critically ill adults in China: a prospective, observational study
title_full Serum N-terminal pro-B-type natriuretic peptide and cystatin C for acute kidney injury detection in critically ill adults in China: a prospective, observational study
title_fullStr Serum N-terminal pro-B-type natriuretic peptide and cystatin C for acute kidney injury detection in critically ill adults in China: a prospective, observational study
title_full_unstemmed Serum N-terminal pro-B-type natriuretic peptide and cystatin C for acute kidney injury detection in critically ill adults in China: a prospective, observational study
title_short Serum N-terminal pro-B-type natriuretic peptide and cystatin C for acute kidney injury detection in critically ill adults in China: a prospective, observational study
title_sort serum n-terminal pro-b-type natriuretic peptide and cystatin c for acute kidney injury detection in critically ill adults in china: a prospective, observational study
topic Intensive Care
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887693/
https://www.ncbi.nlm.nih.gov/pubmed/36717146
http://dx.doi.org/10.1136/bmjopen-2022-063896
work_keys_str_mv AT dengjia serumnterminalprobtypenatriureticpeptideandcystatincforacutekidneyinjurydetectionincriticallyilladultsinchinaaprospectiveobservationalstudy
AT helinling serumnterminalprobtypenatriureticpeptideandcystatincforacutekidneyinjurydetectionincriticallyilladultsinchinaaprospectiveobservationalstudy
AT liangyufan serumnterminalprobtypenatriureticpeptideandcystatincforacutekidneyinjurydetectionincriticallyilladultsinchinaaprospectiveobservationalstudy
AT hulinhui serumnterminalprobtypenatriureticpeptideandcystatincforacutekidneyinjurydetectionincriticallyilladultsinchinaaprospectiveobservationalstudy
AT xujing serumnterminalprobtypenatriureticpeptideandcystatincforacutekidneyinjurydetectionincriticallyilladultsinchinaaprospectiveobservationalstudy
AT fangheng serumnterminalprobtypenatriureticpeptideandcystatincforacutekidneyinjurydetectionincriticallyilladultsinchinaaprospectiveobservationalstudy
AT liying serumnterminalprobtypenatriureticpeptideandcystatincforacutekidneyinjurydetectionincriticallyilladultsinchinaaprospectiveobservationalstudy
AT chenchunbo serumnterminalprobtypenatriureticpeptideandcystatincforacutekidneyinjurydetectionincriticallyilladultsinchinaaprospectiveobservationalstudy